MP
PVLA

Mangrove Partners’s Palvella Therapeutics PVLA Stock Holding History

Mangrove Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,791
Closed -$223K – 613
2026
Q1 		$223K Buy
+1,791
New +$187K 0.02% 329

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Mangrove Partners's PVLA Position: Q2 2026 in Review

Mangrove Partners sold out of Palvella Therapeutics (PVLA) in Q2 2026, closing a stake of 1,791 shares — an estimated $223K sold.

Mangrove Partners first reported a position in PVLA in Q1 2026 and held it in 1 quarter. The position peaked at $223K in Q1 2026. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Mangrove Partners reported no remaining Palvella Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mangrove Partners sold 1,791 Palvella Therapeutics shares in Q2 2026, an estimated $223K.
  • Mangrove Partners first reported a position in Palvella Therapeutics in Q1 2026 and held it in 1 quarter.
  • Mangrove Partners's Palvella Therapeutics position peaked at $223K in Q1 2026.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.